Impact of long-acting implantable LYR-210 corticosteroid matrices on quality of life of patients with chronic rhinosinusitis in the LANTERN study.

CRS carries significant disease burden that negatively impacts the QoL of patients. Long-acting, local anti-inflammatory treatments that improve the QoL of CRS patients are needed. LYR-210 (7500μg) significantly improved scores for SNOT-22 subdomains and SF-36v2 at week 24. This article is protected by copyright. All rights reserved.